- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04085302
TARA Working Prototype Engagement Evaluation: Feasibility Study
Mixed Methods (Quantitative, Qualitative) Feasability Study Assessing Engagement With the First Version of the TARA Working Prototype (a Digital Behaviour Change Intervention, DBCI) in Individuals With COPD
TARA is a Digital Behaviour Change Intervention (DBCI) for individuals with Chronic Obstructive Pulmonary Disease (COPD)(IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology. HCD involves, among other elements, members of the target audience in evaluations at multiple stages within the design process.
This feasibility study is primarily designed to assess the acceptability of the DBCI test asset to the target audience. Acceptability as defined for the purpose of this study includes usability of the system, and perceived value and desirability to the end-user audience. As such, engagement in this context is deemed to mean the degree to which the test asset provides a usable, acceptable, desirable and valuable experience to its users during a time-limited trial.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Massachusetts
-
Somerville, Massachusetts, Spojené státy, 02144
- Medullan
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Signed and dated written electronic informed consent (e-consent) in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the study
- Male or female patients
- All patients must have a self-reported confirmation of a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD)(or chronic bronchitis or emphysema)
- Age ≥ 40 years
- Patients must be current or ex-smokers with a smoking history of at least 10 pack-years (pack years = [cigarettes per day/20] x years of smoking)
- Modified Medical Research Council (mMRC) Score ≥ 1 (i.e. evidence of activity-related breathlessness)
- Patients must have a current prescription for once daily maintenance bronchodilator in keeping with their approved labels as well as a short-acting bronchodilator ("rescue medication") for at least 3 months prior to study enrolment
- Participants must be willing to use a smart watch and be willing to complete all data collection requirements (within TARA plus phone interview plus on-line questionnaires)
- Patients must confirm that his/her treating physician has been informed about the patient's participation in the study (prior to TARA log-in)
- Fluency in written English
- Currently residing in US (for duration of study)
- Not fully adherent (self-report) to once daily inhaled COPD medication (<80% on a protocol-specific participant self-assessment scale of medication adherence (0 - 100%))
- Access to (and comfort with) a digital device (Desktop; Laptop; Tablet), with updated Firefox [version 67.0 and above] or Chrome [version 75.0.3770.80 and above] browsers installed (or willing to download up-to-date version for the study), and daily home access to internet
- Need to have personal e-mail account that is used daily
Exclusion Criteria:
- Patients with asthma
- Patients who are currently prescribed oxygen therapy
- Patients who have completed a pulmonary rehabilitation (PR) program in the 6 weeks prior to enrolment or patients who are currently in a PR program (rationale: PR programs typically include a self-management component which may interfere with study objectives)
- Planned vacation period during the study period that requires overnight stays away from home
- Major surgery performed within 6 weeks prior to enrolment or planned within 2 months after enrolment, e.g. hip replacement
- Previous enrolment in this study
- Currently enrolled in another investigational device or drug study/trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s)
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Current use of a Smartwatch and/or wrist-worn step counter and not willing to switch to the study-specific Smartwatch for the duration of study
- Any medical or neuro-cognitive condition that would limit the ability of the participant to consent
- Further exclusion criteria apply
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Proveditelnost zařízení
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Všechny předměty
|
14 days
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
% of study participants achieving 80% or higher engagement score with their personal TARA program
Časové okno: Up to 14 days
|
Up to 14 days
|
|
Study participant's motivation to engage with the TARA working prototype (version 1) and their perceptions of value and usefulness
Časové okno: Up to 14 days
|
Qualitative assessment of motivation and perceptions of value and usefulness at different stages in the participant's journey through the prototype; data sourced via discussion in an exit interview at the end of the study.
|
Up to 14 days
|
Evidence of usability issues, patterns of dis-engagement or failures of use in particular pages or functional areas of the prototype
Časové okno: Up to 14 days
|
Analysis of usage data of the site to explore if there are common points at which participants fail to progress, make mistakes or abandon interactions; Data will be sourced from individual and amalgamated usage analytics - data points will include drop-out rates for each of the main functional areas of the site and will be supplemented by within-page usage data An overall score for perceived ease-of-use will be generated using the 'System Usability Scale' (SUS), using self-reported data from the pre- and post-TARA participant questionnaire
|
Up to 14 days
|
Study participant's reports of usability or other issues from using the prototype
Časové okno: Up to 14 days
|
Up to 14 days
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
% of study participants who achieve a score of 8 or greater in Knowledge, Motivation, Confidence (KMC) assessments
Časové okno: Up to 14 days
|
Up to 14 days
|
% of study participants who achieve a positive change in measures of motivation, activation, competence (self-efficacy) and stage of change
Časové okno: Up to 14 days
|
Up to 14 days
|
% of study participants who report increases in adherence to once daily inhaled medication and reduction in Chronic Obstructive Pulmonary Disease (COPD) symptoms
Časové okno: Up to 14 days
|
Up to 14 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 0352-2133
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Digital Behaviour Change Intervention
-
Idaho State UniversityZatím nenabírámeExperimentální videohry | Hodnocení chování
-
Mount Sinai Hospital, CanadaCanadian Institutes of Health Research (CIHR); MOUNT SINAI HOSPITAL; Trillium...NáborStarší dospělí s komplexními potřebami péčeKanada
-
Royal Holloway UniversityBarts & The London NHS Trust; Chelsea and Westminster NHS Foundation TrustZatím nenabíráme
-
Columbia UniversityNational Institute of Nursing Research (NINR)DokončenoAntikoncepční chováníSpojené státy
-
Allurion TechnologiesDokončeno
-
University of FloridaNáborBolesti zad, mechanické | Akutní bolestSpojené státy
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)NáborPre-expoziční profylaxe HIVSpojené státy